GlassScriptPhysician profile
Asheesh Lal
NPI 1841223047
$5,669.68
in general payments reported to CMS, 2019-2025
26 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.67 · 2020: $136 · 2021: $3,952 · 2022: $22.08 · 2023: $144 · 2024: $610 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.21 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $3,040.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $900.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $418.22 | 2023-2025 | |
| Celgene Corporation | $175.39 | 2023-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $146.14 | 2021-2025 | Trodelvy |
| Pfizer INC. | $114.19 | 2023-2025 | |
| Abbvie INC. | $109.72 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.83 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $90.74 | 2024-2025 | Injectafer, Enhertu, Datroway |
| Janssen Biotech, INC. | $85.37 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Astellas Pharma US INC | $75.99 | 2020 | |
| Glaxosmithkline, LLC. | $60.92 | 2025 | Ojjaara, Blenrep |
| Genentech USA, INC. | $44.93 | 2019 | |
| Karyopharm Therapeutics INC. | $43.72 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $35.46 | 2022-2024 | Lynparza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.94 | 2025 | |
| Array Biopharma INC | $27.40 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Taiho Oncology, INC. | $24.33 | 2025 | |
| Springworks Therapeutics, INC. | $23.60 | 2024 | Ogsiveo |
| Kite Pharma, INC. | $22.60 | 2025 | Yescarta |
| Adc Therapeutics America, INC. | $19.37 | 2025 | |
| Tempus Ai, INC | $16.70 | 2025 | Xt Cdx |
| Medtronic USA, INC. | $16.10 | 2020 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Merck Sharp & Dohme LLC | $15.90 | 2019 | |
| Mirati Therapeutics, INC. | $14.13 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asheesh Lal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.